NFS1 and hepatocellular carcinoma: Additionally, the study discovered that knocking down NFS1 can inhibit the metastatic ability of HCC cells and increase their vulnerability to ferroptosis, thereby enhancing the therapeutic sensitivity to oxaliplatin.